Novavax (NSDQ:NVAX) saw its stock jump more than 20% in afternoon trading after the European Commission agreed to purchase up to 200 million doses of its vaccine.
The Gaithersburg, Md.–based vaccine maker announced in March that its NVX-CoV2373 vaccine was 96.4% effective against the original SARS-CoV-2 strain in a U.K. trial. The efficacy in a later trial conducted in the U.S. and Mexico was 90.4%, according to a June NIH press release.
But the company had been slow to get its vaccine onto the market. In the U.S., the company plans on filing for emergency use authorization in late September.
Get the full story from our sister site, Drug Discovery & Development.